AGTR1 and early-onset autosomal dominant Alzheimer disease: For example, the design of a compound which processes the inhibitory activity of losartan (AT1 inhibitor) and Lanabecestat (a potent BACE1 inhibitor) could open new paths in the treatment of Alzheimer’s disease.